Memantina Aurobindo (Memantine Hydrochloride)

Memantine hydrochloride works as a non‑competitive antagonist of the NMDA receptor. By blocking excessive calcium influx through the receptor‑associated ion channel, it reduces excitotoxic neuronal damage that contributes to cognitive decline in Alzheimer’s disease.

The dosage of Memantina Aurobindo is determined by the prescribing clinician based on the patient’s condition, age, renal function, and other clinical factors. The prescriber will set the appropriate dose and titration schedule according to current medical guidelines.

Safety data for memantine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas other approved agents such as donepezil, rivastigmine, and galantamine are cholinesterase inhibitors. Memantine is typically used in moderate to severe disease and may be combined with a cholinesterase inhibitor for additive benefit, while the others are often started earlier in the disease course.

Memantina Aurobindo should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

The medication is taken orally, usually once daily, with or without food as directed by the prescriber. Tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious adverse events, although rare, include seizures, cardiac arrhythmias, severe skin reactions such as Stevens‑Johnson syndrome, hepatic dysfunction, and acute hypertension. Patients should be monitored for any new or worsening symptoms and seek medical attention promptly if serious reactions occur.

Memantina Aurobindo is contraindicated in patients with known hypersensitivity to memantine or any of the excipients. Caution is advised for individuals with severe renal or hepatic impairment, a history of seizures, or those taking other NMDA antagonists, as these conditions may increase the risk of adverse effects.